GlassScriptPhysician profile
Matthew Iammatteo
NPI 1346203593
$26,080.56
in general payments reported to CMS, 2019-2025
30 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,466 · 2020: $8,187 · 2021: $4,616 · 2022: $2,766 · 2023: $334 · 2024: $508 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.76 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $23,996.21 | 2019-2022 | |
| Medtronic, INC. | $280.64 | 2022 | |
| Hologic Sales and Service, LLC | $192.83 | 2020-2024 | Fluent Fluid Management System, Aptima, Thinprep 2000 Processor |
| Millicent US INC | $179.27 | 2023-2025 | Femring, Intrarosa |
| Mayne Pharma Commercial LLC | $170.62 | 2021-2025 | |
| Abbvie INC. | $144.08 | 2020-2024 | |
| Applied Medical Resources Corporation | $143.89 | 2021 | |
| Astellas Pharma US INC | $131.39 | 2023-2024 | Veozah |
| Agile Therapeutics, INC. | $94.77 | 2022-2024 | Twirla |
| Myovant Sciences INC. | $90.40 | 2021-2022 | |
| Pfizer INC. | $85.26 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $79.10 | 2023-2024 | Myfembree |
| Amag Pharmaceuticals, INC. | $74.24 | 2019 | |
| Therapeuticsmd, INC. | $59.59 | 2019-2022 | |
| Exeltis, USA INC. | $50.00 | 2024-2025 | Slynd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $39.76 | 2021-2023 | Balcoltra |
| Baxter Healthcare | $39.13 | 2024 | Perclot |
| Organon LLC | $32.27 | 2024-2025 | Jada System |
| Evofem Biosciences, INC. | $30.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.08 | 2025 | |
| Mimedx Group, INC. | $23.44 | 2025 | |
| Sanofi Pasteur INC. | $16.55 | 2024 | |
| Merck Sharp & Dohme LLC | $16.19 | 2024 | Gardasil, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Optumhealth Care Solutions, LLC | $14.20 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Vertical Pharmaceuticals, LLC | $13.99 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.45 | 2022 | |
| Dysis Medical, INC. | $13.07 | 2021 | |
| Minerva Surgical, INC | $12.16 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Iammatteo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.